Regeneron’s Inmazeb drug receives FDA approval for treating Ebola virus
Category: #headlines  By Nikita Chaurasia  Date: 2020-10-16
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Regeneron’s Inmazeb drug receives FDA approval for treating Ebola virus

According to reliable sources, New York-headquartered biotechnology company, Regeneron Pharmaceuticals Inc. has recently made it to the headlines after its patented Inmazeb drug received approval from the U.S. FDA (Food & Drug Administration) for the treatment of the Ebola virus.

For the record, Inmazeb is a mixture of three monoclonal antibodies, namely maftivimab, atoltivimab, and odesivimab-ebgn. The drug stops the spread of Ebola virus by inhibiting glycoprotein present on the surface of this virus. The antibodies present in it can bind to this glycoprotein and block attachment and virus invasion into healthy cells.

Reportedly, Inmazeb was initially evaluated in a clinical trial round called the PALM trial, that included over 382 individuals infected with the Ebola virus. The trial round was conducted amidst the Ebola virus outbreak between 2018 and 2019 and was led by the Institut National de Recherche Biomédicale along with the U.S. National Institutes of Health.

It is to be noted that the initial symptoms observed after the dosage of Inmazeb included vomiting, tachypnea, tachycardia, chills, and fever. In this context, Regeneron was reported stating that the treatment can give rise to infusion-related events such as hypersensitivity and subsequently discontinued the trial.

However, a recent study by Regeneron revealed that the treatment of patients with Ebola virus using Inmazeb revealed a primary efficacy end point of over 28-day mortality. Additionally, 51% of the 154 patients involved in the study showed rapid recovery.

Regeneron Pharmaceuticals Inc. is reportedly working on the development of REGN-COV2, a drug aimed at the treatment of the COVID-19 virus.

In other news, American multinational pharmaceutical company, Pfizer Inc. has reportedly received provisional determination from the Australian regulatory body, TGA (Therapeutic Goods Administration) for its COVID-19 vaccine, mRNA (messenger ribonucleic acid).

Source credits:

Reference link: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Moderna failed to meet FDA’s requirements for COVID-19 booster vaccines

Moderna failed to meet FDA’s requirements for COVID-19 booster vaccines

By Nikita Chaurasia

Scientists from the U.S. Food and Drug Administration (FDA) claimed that Moderna did not meet all the requirements to support the use of COVID-19 booster shots. This is because the first two shots already showed a strong efficacy rate. Documents rel...

Canada’s healthcare sector likely to brace for looming staff shortages

Canada’s healthcare sector likely to brace for looming staff shortages

By Nikita Chaurasia

According to reliable sources, Canada’s overworked healthcare sector is now bracing for upcoming staff shortages and potential layoffs, as the country accelerates its vaccination drive before the deadline. The development comes at a time when l...

Rocket Lab, Kineis sign multi-launch contract for IoT constellation

Rocket Lab, Kineis sign multi-launch contract for IoT constellation

By Nikita Chaurasia

The space industry is booming as new companies with fresh ideas for space-based applications take advantage of declining launch and satellite costs. Out of those firms, Rocket Lab USA bagged a contract to launch 25 satellites on five missions exclusi...